Research & Discoveries

Eli Lilly Says Its Weight Loss Drug Reduces Diabetes Risk by 94 Percent

Tirzepatide, the active ingredient in Mounjaro and Zepbound, delayed patients’ progression to Type 2 diabetes.
Eli Lilly Says Its Weight Loss Drug Reduces Diabetes Risk by 94 Percent
An Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, N.J., on March 5, 2021. Mike Segar/Reuters
Huey Freeman
|Updated:
0:00

A prescription drug injected weekly to help reduce weight in overweight and obese people was shown to significantly reduce the risk of Type 2 diabetes (T2D).

Tirzepatide, the active ingredient in Mounjaro and Zepbound, was shown to reduce the progression of T2D by 94 percent, according to a press release from Eli Lilly and Co., the drug’s manufacturer, on Tuesday.

Huey Freeman
Huey Freeman
Author
A newspaper reporter, editor, and author, Huey Freeman recently wrote “Who Shot Nick Ivie?” a true crime book on the murder of a border patrol agent. He lives in Central Illinois with his wife Kate.